Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Depreciation & Amortization - Total (2017 - 2021)

Lexaria Bioscience's Depreciation & Amortization - Total history spans 5 years, with the latest figure at $27929.0 for Q2 2021.

  • Quarterly results put Depreciation & Amortization - Total at $27929.0 for Q2 2021, down 0.54% from a year ago — trailing twelve months through Feb 2022 was $27929.0 (down 75.24% YoY), and the annual figure for FY2020 was $112750.0, up 86.21%.
  • Depreciation & Amortization - Total for Q2 2021 was $27929.0 at Lexaria Bioscience, roughly flat from $27930.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization - Total ranged from a high of $28875.0 in Q3 2020 to a low of $375.0 in Q4 2017.
  • The 5-year median for Depreciation & Amortization - Total is $26195.0 (2019), against an average of $17293.0.
  • The sharpest move saw Depreciation & Amortization - Total soared 4200.95% in 2019, then decreased 1.24% in 2021.
  • Year by year, Depreciation & Amortization - Total stood at $375.0 in 2017, then skyrocketed by 327.47% to $1603.0 in 2018, then skyrocketed by 1616.28% to $27512.0 in 2019, then grew by 1.52% to $27929.0 in 2020, then changed by 0.0% to $27929.0 in 2021.
  • According to Business Quant data, Depreciation & Amortization - Total over the past three periods came in at $27929.0, $27930.0, and $27929.0 for Q2 2021, Q1 2021, and Q4 2020 respectively.